CAMBRIDGE, MA

YOU'RE INVITED

The PolyBio Convergence Summit

Pathogen persistence across chronic disease and aging

November 18–20, 2026 · American Academy of Arts and Sciences · Cambridge, MA · By invitation only

WHY NOW

Advancing a new understanding of how persistent pathogens drive chronic disease.

PolyBio has become a global leader in applying next-generation technologies to uncover how viral, bacterial, parasite and other pathogens contribute to chronic disease.

Working across a global research consortium, PolyBio has helped reveal biological mechanisms linking persistent infection to Long COVID, neurodegenerative disease, autoimmune disorders, chronic tick-borne illness, and the biological processes underlying aging.

But understanding disease biology is only the beginning. PolyBio is now building the infrastructure needed to translate these discoveries into advanced diagnostics, biomarker-driven clinical trials, and new treatments—accelerating the path from scientific discovery to patient care.

THE NETWORK

We've spent years building the network.

For years, PolyBio has connected investigators across 25+ leading academic institutions studying infection-associated chronic disease. More recently, we've expanded that network to include diagnostic developers, biotechnology and pharmaceutical leaders, commercialization experts, clinical trialists, medical educators, and regulatory leaders.

Because of these relationships, we know many of the people shaping the future of the field. Yet these communities rarely have the opportunity to work together, slowing the development of the diagnostics, clinical trials, and treatments patients urgently need.

That changes now.

CONSORTIUM PROJECT EXPLORER

WHY THIS ROOM

That’s why we created the Summit.

For the first time, everyone driving advancement in infection-associated chronic disease will converge in one room.

01

The researchers uncovering disease biology

02

The engineers building new diagnostics

03

The companies translating discoveries

04

The clinicians treating patients

05

The regulators defining approval pathways

06

The investors helping technologies reach the clinic

07

The patients whose experience continues to shape the science

The people capable of transforming this field already exist. For the first time, they’ll work side by side to accelerate solutions for patients. That's exactly why we want you in it.

THE PROGRAM

One continuous pathway from discovery to patient care.

We didn't want a wall of sessions. The whole Summit runs on one arc, each part handing off to the next.

01

The biology

Pathogen persistence in Long COVID, Lyme, and across Alzheimer's, MS, and aging

02

The detection

A new generation of diagnostics for hard-to-find infection

03

The translation

Turning tests and targets into real-world validation and reimbursement

04

The treatment

Therapies and trials for persistent infection

05

The scaling

Medical education and public–private partnerships to maximize innovation

Each day features cross-sector panels. Days one and two close with an evening reception and dinner.

WHO'S PRESENTING

The people defining the field — across every stage.

DISEASE MECHANISMS

Timothy Henrich, MD

UCSF

Nadia Roan, PhD

Gladstone Institutes

Lena Pernas, PhD

UCLA

Benjamin Readhead, PhD

University of Arizona

Ian Crozier, MD

Frederick National Laboratory

ADVANCED DIAGNOSTICS

Shannon Stott, PhD

Boston University

David Walt, PhD

Harvard University

Christos Petropoulos, PhD

Labcorp–Monogram Biosciences

Devon Campbell

Prodct

Brandon Johnson

StudioDx

NOVEL TREATMENTS

Steven Deeks, MD

UCSF

Andrea Schietinger, PhD

Memorial Sloan Kettering

Jeffrey Ulmer, PhD

TechImmune

Marc Elia

Invivyd

Jeffrey Dow

60 Degrees Pharmaceuticals

HEALTHCARE INNOVATION

Michael Mina, MD, PhD

AnywhereDx

David Putrino, PhD

Mount Sinai

Brittany Caldwell, PhD

FDA

Brian Wang, PhD

ARIA

Shelby O'Connor, PhD

University of Wisconsin / Inkfish

A partial list — confirmed and invited speakers, with more announcing soon. Amy Proal, PolyBio, chairs the Summit.

HOW THE DAYS WORK

Every session is designed to create new collaborations.

01

Field-defining keynotes

The leading voices frame the questions the whole field will work to answer.

02

Cross-sector problem solving

Curated panel sessions maximize how researchers, diagnostics companies, industry leaders and other stakeholders tackle the same scientific questions together.

03

Ideas that travel

Our on-site podcast with Matt Kaeberlein extends the Summit's reach well beyond the room. The Summit will also be livestreamed free of charge, making its conversations accessible to a global audience.

04

Collaborations by design

You'll see who's coming and can book 1:1s and side sessions in advance, so you can plan the meetings you want and still leave room for the ones you don't expect.

05

A blueprint for the field

We capture the Summit's conclusions in a white paper shared across the entire field.

THE VENUE

We chose a beautiful historic venue.

We're holding the Summit at the American Academy of Arts and Sciences in Cambridge — one of the country's oldest and most respected learned societies, founded in 1780 by John Adams and John Hancock. The campus combines historic significance with modern meeting spaces designed for conversation, discovery, and partnership. Holding it here says this work deserves to sit alongside the most important science of our time.

THE COMMITMENT

The Summit runs as one program across three days.

Please register only if you can be there for the full program, November 18–20.

Each day picks up where the last one left off, and we're keeping the room to about 200 people so everyone has a real chance to talk. The collaborations we're hoping for usually start on the second or third conversation with someone, not the first. Space is genuinely tight, so if you can only make part of it, we'd rather hold your seat for someone who can be there throughout.

Invite-only, capped at ~200

Three full days, November 18–20

Breakfast and lunch daily, dinner nights one and two

Registration code included in your invitation email.

TRAVEL & LOGISTICS

Getting here.

VENUE

American Academy of Arts and Sciences

136 Irving Street, Cambridge, MA 02138

DROP-OFF & VEHICLE ENTRANCE

200 Beacon Street, Somerville, MA 02143

All cars, taxis and rideshares. No parking on site.

WHERE TO STAY

Cambria Hotel

Somerville, a short ride from the venue. Special room block for those who book early.

Sheraton Commander

16 Garden Street, on Cambridge Common

The Charles Hotel

1 Bennett Street, Harvard Square

Cambridge Common House

2 Garden Street, 16 rooms — book early

Attendees book and pay for their own rooms.

GETTING THERE

By air — Boston Logan (BOS), about 25 minutes by car.

By T — Red Line to Harvard or Porter Square, then a short ride or walk.

By car or rideshare — use the Beacon Street entrance above; metered street parking nearby is very limited.

LOGISTICS CONTACTS

Justin Taylor

justin@longevitygl.org

Daniel Dacey

daniel.dacey@dovetailbp.com

Reach out with any travel, access, or dietary questions.

Breakfast and lunch each day, plus receptions and dinner on the evenings of November 18 and 19, are hosted by PolyBio.

Given the science we study, we take air quality seriously: HEPA filtration throughout the venue and complimentary COVID and flu tests on site.

JOIN US IN NOVEMBER

Join us as we bring together the people who will define the next decade of infection-associated chronic disease research, diagnostics, and treatment.

Only PolyBio sits at the intersection of academic discovery, diagnostics, biotechnology, clinical trials, commercialization, medical education, and regulatory engagement. We would be honored to have you with us.

Register with the link and code in your invitation email. Standard registration is $600; your fee is waived.

November 18–20, 2026 · American Academy of Arts and Sciences · Cambridge, MA · By invitation only

Amy Proal

CEO, PolyBio Research Foundation

aproal@polybio.org

polybio.org